In the June 16, 2004, issue of BioWorld International, an article on Wilex AG should have said that the most important results from the Phase II trials were seen with the antibody Rencarex used as a monotherapy. The median survival time for the patients in the trial was 16 months; in comparable patient groups receiving systemic standard treatments it is about 10 months. In addition, the company is examining the drug in a non-metastatic setting.

Editor's Note: The correction has been made in BioWorld Online.

No Comments